Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma by Pu, Yeong-Shiau et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
Journal of Biomedical Science
Open Access Research
Characterization of membranous and cytoplasmic EGFR 
expression in human normal renal cortex and renal cell carcinoma
Yeong-Shiau Pu†1, Chao-Yuan Huang†1, Yi-Zih Kuo3, Wang-Yi Kang6, Guang-
Yaw Liu5, A-Mei Huang3,4, Hong-Jeng Yu1, Ming-Kuen Lai1,2, Shu-
Pin Huang7, Wen-Jeng Wu7, Shean-Jaw Chiou3 and Tzyh-Chyuan Hour*3,4
Address: 1Department of Urology, National Taiwan University College of Medicine, Taipei, Taiwan, Republic of China, 2Department of Oncology, 
National Taiwan University College of Medicine, Taipei, Taiwan, Republic of China, 3Institute of Biochemistry, Kaohsiung Medical University, 
Kaohsiung, Taiwan, Republic of China, 4Center of Excellent for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, 
Republic of China, 5Institute of Immunology, Chung Shan Medical University, Taichung, Taiwan, Republic of China, 6Department of Pathology, 
Kuo General Hospital, Tainan, Taiwan, Republic of China and 7Department of Urology, Kaohsiung Medical University Chung-Ho Memorial 
Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, Republic of China
Email: Yeong-Shiau Pu - yspu@ntu.edu.tw; Chao-Yuan Huang - cyhuang0909@ntu.edu.tw; Yi-Zih Kuo - u8806007@yahoo.com.tw; Wang-
Yi Kang - kawaii@cc.kmu.edu.tw; Guang-Yaw Liu - liugy@csmu.edu.tw; A-Mei Huang - amhuang@cc.kmu.edu.tw; Hong-
Jeng Yu - yhj5251@ha.mc.ntu.edu.tw; Ming-Kuen Lai - mingkuen@ntu.edu.tw; Shu-Pin Huang - shpihu@yahoo.com.tw; Wen-
Jeng Wu - wejewu@kmu.edu.tw; Shean-Jaw Chiou - sheanjaw@cc.kmu.edu.tw; Tzyh-Chyuan Hour* - cliff@cc.kmu.edu.tw
* Corresponding author    †Equal contributors
Abstract
Metastatic renal cell carcinoma (RCC) is highly resistant to conventional systemic treatments,
including chemotherapy, radiotherapy and hormonal therapies. Previous studies have shown over-
expression of EGFR is associated with high grade tumors and a worse prognosis. Recent studies
suggest anticancer therapies targeting the EGFR pathway have shown promising results in clinical
trials of RCC patients. Therefore, characterization of the level and localization of EGFR expression
in RCC is important for target-dependent therapy. In this study, we investigated the clinical
significance of cellular localization of EGFR in human normal renal cortex and RCC. RCC and
adjacent normal kidney tissues of 63 patients were obtained for characterization of EGFR
expression. EGFR protein expression was assessed by immunohistochemistry on a scale from 0 to
300 (percentage of positive cells × staining intensity) and Western blotting. EGFR membranous
staining was significantly stronger in RCC tumors than in normal tissues (P < 0.001). In contrast,
EGFR cytoplasmic staining was significantly higher in normal than in tumor tissues (P < 0.001). The
levels of membranous or cytoplasmic EGFR expression in RCC tissues were not correlated with
sex, tumor grade, TNM stage or overall survival (P > 0.05). These results showed abundant
expression of membranous EGFR in RCC, and abundant expression of cytoplasmic EGFR in normal
tissues. EGFR expression in RCC was mostly located in the cell membrane, whereas the EGFR
expression in normal renal tissues was chiefly seen in cytoplasm. Our results suggest different
locations of EGFR expression may be associated with human renal tumorigenesis.
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Introduction
Renal cell carcinoma (RCC) arises mainly from renal
tubular epithelia [1]. Surgical resection of the diseased tis-
sue has been considered the only curative treatment [2].
Metastatic RCC is highly resistant to conventional sys-
temic treatments, including chemotherapy, radiotherapy
and about 10-20% of patients respond to cytokine-based
immunotherapy [3]. Development of targeted therapies
in renal cell cancer is largely due to the fact that a growing
understanding of the underlying molecular biology of
RCC has established the vascular endothelial growth fac-
tor (VEGF) and mammalian target of rapamycin (mTOR)
pathways as relevant therapeutic targets in RCC [3,4].
Despite the treatments available nearly all patients die of
metastatic disease. Many studies have demonstrated
genetic and environmental factors lead to RCC occurring
during a protracted period of tumorigenesis [4]. It seemed
desirable to identify and characterize potential molecular
markers appearing during of tumorigenesis which might
provide rapid and effective possibilities for early detection
of RCC [5].
Epidermal growth factor receptor (EGFR) is classified into
a family of four closely related cell membrane receptors:
EGFR (HER1; ErbB1), HER2 (ErbB2), HER3 (ErbB3), and
HER4 (ErbB4) [6]. These receptors are glycoproteins of
transmembrane with an extracellular ligand binding
domain and an intracellular domain with tyrosine kinase
activity involved in signal transduction [7]. EGFR activa-
tion induces the cell cycle progression, inhibition of apop-
tosis and angiogenesis, promotion of invasion/metastasis,
and other tumor promoting activities [8,9]. EGFR overex-
pression has been associated with an aggressive clinical
course in many cancers [10-12]. RCCs frequently show
EGFR immunoreactivity [13,14]. Previous studies have
shown p-regulation of EGFR is one of the common events
in RCC tumorigenesis [15]. Over-expression of EGFR is
thought to play an important role in tumor initiation and
progression of RCC, since up-regulation of EGFR has been
associated with high grade and a worse prognosis [16,17].
This is particularly interesting because recently, anticancer
therapies targeting the EGFR pathway have shown prom-
ising results in clinical trials of RCC patients [18,19].
Recent studies suggest the existence of a novel role of
EGFR signaling pathway where activated EGFR undergoes
nuclear translocalization, subsequently regulating gene
expression and potentially mediating specific cellular
processes [20-22]. This new role of EGFR is distinct from
the well-known traditional EGFR involving transduction
of mitogenic signals through activating multiple signaling
cascades [23]. These results point out EGFR may play a
novel role as a cytoplasmic/nuclear shuttling transcription
factor in tumor progression [24]. Interestingly, Kallio et al.
also reported the membranous and cytoplasmic locations
of the EGFR immunostaining in RCC [25]. The different
locations of EGFR immunostaining may be associated
with progression and prognosis in RCC [26,27]. It is likely
knowledge of the relationship between differential expres-
sion and cellular localization of EGFR and its ligands in
normal and neoplastic lesions and patient survival might
be beneficial in developing potential targeted agents for
cancer therapy. Therefore, identifying the level and locali-
zation of EGFR expression in RCC is important for target-
dependent therapy. However, characterization of distribu-
tion and localization of EGFR in normal kidneys and RCC
tissues from the same patient have not been examined.
Thus we supposed the different locations of EGFR expres-
sion may be associated with human renal tumorigenesis.
In this study, we examined the cellular localization of
EGFR in RCC tumor portion and normal-looking renal
cortical tissue from the same patient.
Materials and methods
Clinicopathological characteristics
This study had 63 patients with RCC, 46 males and 17
females with a mean age of 62 years. Each pair of tissues
included a RCC tumor portion and normal-looking renal
cortical tissue from the same patient. These specimens
were obtained from nephrectomies carried out at the
National Taiwan University Hospital (NTUH). Fuhrman's
nuclear grading system from I to IV was used [28]. The
grade I, II, III and IV classifications were present in 9
(14%), 29 (46%), 9 (14%), 14 (23%) cases and 2 cases
(3%) were not determined, respectively. Tumors were
staged according to the TNM system and histologically
classified according to the WHO guidelines [29]. Tumors
were further staged into 41 cases (65%) as being organ-
confined (T1-2N0M0), 15 cases (24%) were locally
advanced (T3-4N0M0) and 7 cases (11%) were metastatic
(any T with N1-2 or M1). Clinicopathological characteris-
tics of the tumors are summarized in Table 1. Approval
from the Institutional Review Boards of NTUH and Kaoh-
siung Medical University were obtained and informed
consent was received from all participating patients.
Immunohistochemistry (IHC)
Immunostaining was performed on paraffin sections by
the avidin-biotin- peroxidase complex method, using a
Super SensitiveTM Link-Label IHC Detection System (Bio-
Genex, CA, USA). In brief, the sections were de-paraffin-
ized in xylene and rehydrated through graded alcohols,
then boiled in 0.01 M citrate buffer (pH 6.0) for 10 min.
Hydrogen peroxide, 0.3%, was added to block any endog-
enous peroxidase activity. To block nonspecific binding
the sections were incubated with a goat serum blocking
solution composed of 10% normal goat serum in phos-
phate buffer saline, pH7.4 and 0.05% sodium azide. The
sections were incubated with anti-EGFR antibody (SantaJournal of Biomedical Science 2009, 16:82 http://www.jbiomedsci.com/content/16/1/82
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Cruz Biotechnology Inc, Santa Cruz, CA) used at 1:100
dilution at 4°C overnight. Horseradish peroxidase (HRP)
polymer conjugated was used as a second antibody to
avoid contaminating endogenous biotin or streptavidin
(Zymed). After washing, the antigen-antibody complex
was applied and stained with diaminobenzidine (Golden
Bridge, Mukilteo, WA). Counterstaining was performed
lightly with hematoxylin. Specific staining for EGFR was
seen as a brown color in the cytoplasm or membrane,
respectively. Breast cancer tissues served as a positive con-
trol of EGFR. Pre-immune serum was used instead of the
first antibody as a negative control. All the control slides
yielded negative results. Expression of EGFR was evalu-
ated according to the ratio of positive cells and the stain-
ing intensity as described previously [30,31]. To semi-
quantitate EGFR membranous and cytoplasmic staining,
the following scoring method was applied. Expression of
membranous EGFR evaluated the intensity of membra-
nous immunostaining and categorized as either 1+
(weak); 2+ (moderate); 3+ (strong). Cytoplasmic staining
was evaluated according to the ratio of positive cells and
staining intensity. The ratio of positive cells each speci-
men was scored from 0~100% of the cells examined.
Intensity was graded as follows: 0, no signal; 1, weak; 2,
moderate and 3, strong staining. A total score of 0 to 300
was finally calculated (percentage of positive cells × stain-
ing intensity). The evaluation of immunostaining was per-
formed by one pathologist (W. Y. K), was unaware of the
tissue site and the fate of the patient.
Isolation of membranous and cytoplasmic protein 
fractions
The cytoplasmic and membranous proteins were
extracted from tissue samples using the ITSIPREP™ Pro-
FEK KIT (ITIS Bioscience, PA, USA). About 50-100 mg of
tissue was used and cut into small pieces. Ice-cold Cytosol
Buffer 1 (0.08% potassium chloride, 0.02% magnesium
chloride, 0.3% HEPES, 006% NP-40 and 0.005% EDTA)
was immediately added using 5× the volume of the tissue,
and homogenized with a homogenization device. The
lysate incubated on ice for 15 min after being mixed with
lysate by vortexing briefly and then centrifuging the sam-
ple at 3,000 × g for 5 min at 4°C. The supernatant was
carefully collected and the pellet was retained. This pellet
was the nuclear-protein enriched. Then the supernatant
was centrifuged at 16,000 × g for 10 min at 4°C, and the
supernatant was transferred into a clean storage tube. This
fraction was the cytosol-protein enriched. Wash Buffer 2
(0.08% potassium chloride, 0.02% magnesium chloride,
0.3% HEPES and 0.005% EDTA) of was added to the
Table 1: Immunostaining expression of membranous EGFR in normal parenchymal and RCC tissues.
Characteristic Patients Membranous EGFR protein expression
(mean score ± SE)
P value*
No. (%) Normal renal tubular cells RCC
Total <0.001
Sex
Male 46 (73) 0.1 ± 0.1 2.1 ± 0.1 <0.001
Female 17 (27) 0.2 ± 0.1 2.1 ± 0.2 <0.001
P value† 0.172 0.98
Grade
I 9 (14) 0.2 ± 0.1 1.9 ± 0.3 0.001
II 29 (46) 0.1 ± 0.1 2 ± 0.2 <0.001
III 9 (14) 0 2.3 ± 0.3 <0.001
IV 14 (23) 0.1 ± 0.1 2.2 ± 0.2 <0.001
ND 2 (3) 0 1.5 ± 0.5
P value‡ 0.679 0.641
Stage
Organ-confined (T1-2N0M0) 41 (65) 0.1 ± 0.1 2.1 ± 0.1 <0.001
Locally advanced (T3-4N0M0) 15 (24) 0.1 ± 0.1 1.9 ± 0.2 <0.001
Metastatic (N1-2 or M1) 7 (11) 0.1 ± 0.1 2 ± 0.4 0.002
P value‡ 0.989 0.766
Histological type
Conventional 54 (86) 0.1 ± 0.1 2.2 ± 0.1 <0.001
Non-conventional 9 (14) 0.1 ± 0.1 1.3 ± 0.4 0.01
P value† 0.894 0.006
NOTE: Expression of membranous EGFR was evaluated the intensity of membranous immunostaining and categorized as either 1+ (weak); 2+ 
(moderate) and 3+ (strong). Non-conventional type included papillary, chromophobe, sarcomatoid and collecting duct. Abbreviations: RCC, renal 
cell carcinoma; SE, standard error; TNM, tumor-node-metastasis; ND, not determined. *: paired sample t test, †: Independent-sample t test for two 
groups, ‡: One-way ANOVA for three or more groups.Journal of Biomedical Science 2009, 16:82 http://www.jbiomedsci.com/content/16/1/82
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nuclear pellet obtained above. The lysate was vortexed
briefly and centrifuged at 3,000 × g for 5 min at 4°C. The
supernatant was discarded and Nuclear Buffer 3 (4%
sodium chloride, 0.02% magnesium chloride, 0.5%
HEPES, 30% glycerol and 0.009% EDTA) was added. The
lysate was incubated on ice for 30 min and vortexed every
10 min. And then the mixture was centrifuged for 10 min
at 16,000 × g at 4°C. The supernatant was carefully col-
lected and transferred to a clean storage tube. This fraction
was the nuclear-protein enriched. The pellet was washed
in the above step with Nuclear Buffer 3, vortexed briefly,
and centrifuged as above. The supernatant was discarded
and Total Membrane Buffer 4 (1% sodium chloride, 0.6%
1 M Tris-HCl pH 8.0, 1.3% NP-40, 0.6% deoxycholic acid,
0.6% sodium monohydrate and 0.2% sodium dodecyl
sulfate) was added using 5× the volume of cell pellet. The
lysate was incubated on ice for 30 min and vortexed every
10 min. It was then centrifuged at 16,000 × g or more for
10 min at 4°C. The supernatant was then carefully col-
lected. This fraction was the membrane-protein enriched.
The extracted membranous and cytoplasmic protein frac-
tions were stored at -80°C for further analysis.
Western blotting analysis
Cells scraped from one 100-mm Petri dish were resus-
pended in 100 μl of RIPA lysis buffer composed of 50 mM
Tris-Cl, pH = 7.5, 1% NP-40, 150 mM NaCl, 10 mM
EDTA, 1 mM sodium vanadate, 0.1% sodium dodecyl sul-
fate, 0.5% sodium deoxycholate, 10 μg/ml aprotinin, 1
mM phenylmethanesulfonyl fluoride, and 10 μg/ml leu-
peptin, and placed on ice for 30 min. The lysate was then
centrifuged at 18,000 g for 30 min at 4°C to provide the
supernatant for protein concentration determination. Cell
extracts (50 μg) were separated on 10% SDS-polyacryla-
mide gels and transferred to immobilon polyvinylidene
difluoride membranes (Millipore, Bedford, MA). After
blocking, the membranes were incubated with human
specific anti-EGFR (Santa Cruz Biotechnology) polyclonal
antibody at 4°C for 12 h, followed by the horseradish per-
oxidase-labeled second antibody, and developed with the
ECL system (Santa Cruz Biotechnology).
Statistical analysis
Data are presented as the mean ± standard error of the
means (SEM). Independent-sample t test and one-way
ANOVA were used to compare protein expression deter-
mined by IHC analysis. Survival data was obtained from
hospital and clinic records. The Kaplan-Meier method was
used to estimate the probability of overall survival. The
log-rank test was performed to examine the association of
EGFR with overall survival. All tests were two-sided with P
< 0.05 being statistically significant.
Results
Expression of membranous EGFR in normal parenchymal 
and RCC tissues
The expression of EGFR protein was estimated in 63 pairs
of tissues by immunohistochemistry (IHC). Membranous
staining of EGFR was noted in normal parenchymal and
RCC tissues. The EGFR protein staining was strongly pos-
itive in RCC cells but weakly positive in most normal
parenchymal cells (Fig.1). IHC expression levels were fur-
ther quantified on the intensity of membranous immu-
nostaining and categorized as either 1+ (weak); 2+
(moderate); 3+ (strong). The IHC score was determined as
the mean expression levels of normal and cancerous tissue
cores analyzed respectively (Table 1). The RCC tissues had
markedly elevated scores of 2.1 ± 0.1 compared to normal
renal tissues scores of 0.1 ± 0.1 (P < 0.001) as presented in
Table 1. The immunostaining of EGFR in normal tissues
showed no signal stain in 88.9% (56 cases), weak stain in
9.5%% (6 cases), moderate stain in 1.6% (1 cases) and
strong stain in 0% (0 cases) of the 63 pair specimens. In
contrast, EGFR immunostaining in cancerous tissues
showed no signal stain in 7.9% (5 cases), weak stain in
11.1% (7 cases), moderate stain in 47.7% (30 cases) and
strong stain in 33.3% (21 cases) of these cases (data not
shown). Similarly, the levels of membranous EGFR pro-
tein were increased in these RCC tissues as estimated by
the protein fraction and Western blotting (Fig. 2). Accord-
ing to histological classification, membranous EGFR pro-
tein was significantly higher in conventional than in non-
conventional RCC (P = 0.006). However, membranous
EGFR levels in the RCC tissues did not differ between gen-
der, age at diagnosis, nuclear grades and tumor stages (all
Ps > 0.05), as shown in Table 1.
Expression of cytoplasmic EGFR in RCC
Specific staining of EGFR was noted in the cytoplasm.
Thus, we examined the cytoplasmic staining of EGFR in
normal parenchymal and RCC tissues by IHC. The IHC
score was determined as the mean expression levels of
normal and cancerous tissue cores analyzed, respectively
(Table 2). The cytoplasmic EGFR protein staining was
strongly positive in normal renal tubular cells but weakly
positive in most cancerous epithelia (Fig. 3). IHC expres-
sion levels were further quantified on a scale from 0 to
300 (percent positive cells ± staining intensity, data not
shown). The IHC score was determined as the mean
expression levels of normal and cancerous tissue cores
analyzed, respectively (Table 2). The normal renal tissues
had markedly elevated scores of 201 ± 10.7 compared to
RCC tissues scores of 103.3 ± 6.4 (P < 0.001) as shown in
Table 2. Similarly, the levels of cytoplasmic EGFR protein
were increased in these normal tissues as estimated by
protein fraction and Western blotting (Fig. 2). However,
the levels of cytoplasmic protein in the RCC tissues did
not differ between gender, age at diagnosis, nuclearJournal of Biomedical Science 2009, 16:82 http://www.jbiomedsci.com/content/16/1/82
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Immunohistochemical staining of membranous EGFR in normal parenchymal and RCC tissues Figure 1
Immunohistochemical staining of membranous EGFR in normal parenchymal and RCC tissues. Tissue sections 
of normal parenchymal tissues (A, C) or RCC (B, D) were from the same patient. The polyclonal anti-EGFR antibody was used 
to stain paraffin sections (A, B). Negative control was the omission of the primary antibody (C, D). The breast cancer used as 
a positive control for EGFR expression (E). Original magnification, × 200.
A B
E
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grades, tumor stages or histological types (all Ps > 0.05),
as shown in Table 2.
EGFR expression and overall survival in RCC patients
To examine if the different locations of EGFR expression
correlated with survival of patients after surgery, Kaplan-
Meier analysis was performed comparing EGFR-positive
with EGFR-negative tumors in RCC patients. Our data
showed a trend that RCC patients with positive expression
of membranous EGFR had a poorer survival outcome
compared with those with negative expression of mem-
branous EGFR (Fig. 4A), although it did not reach statisti-
cal significance (P  = 0.2). Similar trend as depicted in
Figure 4B, showed lower expression of cytoplasmic EGFR
in RCC patients had a poorer survival outcome compared
with those with higher expression of cytoplasmic EGFR.
Although it did not reach the significant correlation
between expression of cytoplasmic EGFR and survival in
RCC patients (P = 0.6). However, the small sample size
may partially explain the lack of statistical significance.
Discussion
In this study, we demonstrated the different locations of
epidermal growth factor receptor (EGFR) immunostain-
ing in renal tumorigenesis from renal cell carcinoma
(RCC) and adjacent normal kidney tissues of 63 patients.
EGFR expression in RCC was mostly located in the cell
membrane, whereas the EGFR expression in normal renal
tissues was chiefly seen in cytoplasm. Our results also
were identical with previous studies showing higher
expression of membranous EGFR frequently was detected
and had a poorer survival outcome in many cancer cells.
Here, our results suggested different locations of EGFR
expression might be associated with human renal tumor-
igenesis.
Previous studies have shown EGFR overexpression in the
advanced stage, poor prognosis and metastatic human
cancer [32]. Over-expression of EGFR played an impor-
tant role in tumor initiation and progression of RCC, so
up-regulation of EGFR was correlated with high-grade
tumors and a worse prognosis [33]. Advanced RCC was
known to be largely resistant to conventional chemother-
apy [34]. As a result, the prognosis for patients with
advanced RCC was extremely poor [35]. Recently, both
laboratory and clinical studies have shown the targeted
agents for treatment of advanced RCC as a potential ther-
apy. Therefore, this was particularly interesting because
recently, anticancer therapies targeting the EGFR pathway
have shown promising results in clinical trials of RCC
patients [36,37]. The prognostic association of EGFR over-
expression in RCC, however, is a controversial issue. Some
studies showed an association of EGFR immunoreactivity
with well differentiated RCCs [38], or regarded strong
membranous EGFR immunostaining as an indicator of
good prognosis [39], whereas others showed an associa-
tion of EGFR immunoreactivity with high tumor stage/
grade and poor prognosis [40], or no significant associa-
tions at all [41]. We found a similar result regarding the
higher expression of membranous EGFR in RCC than in
normal tissues. As expected, there was a trend that RCC
patients with positive expression of membranous EGFR
had a poorer survival outcome compared with those with
negative expression of membranous EGFR. Further, our
study showed there was a significant correlation between
the level of membranous EGFR expression and histologic
subtypes, with higher expression in conventional than in
non-conventional RCC (including papillary, chromo-
phobe, sarcomatoid and collecting duct). Previous studies
indicated cytoplasmic EGFR immunostaining was associ-
ated with high tumor stage, grade and poor prognosis in
RCCs [42,43]. The similar adverse prognostic [44] role of
Detection of membranous and cytoplasmic EGFR in normal  parenchymal and RCC tissues Figure 2
Detection of membranous and cytoplasmic EGFR in 
normal parenchymal and RCC tissues. The total, mem-
branous and cytoplasmic protein fractions were extracted 
from tissue samples. The total (50 μg), membranous (80 μg) 
and cytoplasmic (50 μg) fractions were subjected to Western 
blotting with anti-EGFR antibody. β-actin and α-tubulin rep-
resented the loading internal controls, respectively.
-actin
N1 T1
EGFR
N2 T2
Membranous
-tubulin
EGFR
N1 T1 N2 T2
Cytoplasmic
N1 T1 N2 T2
Total protein
EGFR
-tubulinJournal of Biomedical Science 2009, 16:82 http://www.jbiomedsci.com/content/16/1/82
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cytoplasmic EGFR has been shown in squamous cell car-
cinoma of the lung. Chandrika et al noted the different
locations and level of EGFR expression in normal and can-
cerous lesions of lung [44], and suggested this switch from
greater cytoplasmic EGFR to greater membranous EGFR
expression might occur at the stage of dysplasia. Similarly,
the aberrant cellular location of some adhesion molecules
such as alpha-catenin may result in tumor dedifferentia-
tion and aggressive, metastatic phenotype in laryngeal car-
cinoma [45]. Interestingly, we also found similar results
that EGFR expression in RCC was mostly located in the
cell membrane, whereas the EGFR expression in normal
renal tissues was primarily occurred in the cytoplasm.
Based on our results, we suggest different locations of
EGFR expression may be associated with human renal
tumorigenesis. However, the cellular localization (mem-
brane versus cytoplasmic) of EGFR in RCC has not been
addressed previously. The overexpression of EGFR in the
cytoplasm of renal cortex may reflect receptor-ligand
internalization, a rapid process occurring after ligand
binding [46]. Although internalized receptors in most cell
lines have been shown to be rapidly degraded [47,48],
Dunn et al found a proportion of internalized receptor in
EGF-treated hepatocytes was recycled to the cell surface
[49]. However, we can't exclude the possibility intracellu-
lar localization of EGFR may be newly synthesized mole-
cules within the endoplasmic reticulum or Golgi that have
yet to be processed and inserted into the membranes.
Endocytic downregulation of signaling receptors has been
regarded solely as a means of attenuating receptor signal-
ing [50]. Recent study indicated that EGFR endocytosis
was not only a way to inhibit activated receptors; it might
also be a regulatory mechanism to control the expression
of EGFR signaling [50,51]. Impaired endocytic downregu-
lation of signaling receptors is frequently associated with
cancer, since it can lead to increased and uncontrolled
receptor signaling. In our study, may further demonstrate
the mostly EGFR was expressed in cytoplasm through the
regulatory mechanism of endocytic downregulation in
normal kidney cells, whereas mostly EGFR can escape
endocytic downregulation and expressed in membrane of
RCC. However, further studies were needed to determine
the biological role and clinical significance of EGFR loca-
tion in RCC.
To our knowledge, this is the first study to demonstrate
the EGFR location in normal and RCC tissues. Future
studies should aim at answering the question of whether
different patterns of immunoreactivity (membranous ver-
Table 2: Immunostaining expression of cytoplasmic EGFR in normal parenchymal and RCC tissues.
Characteristic Patients Cytoplasmic EGFR protein expression
(mean score ± SE)
P value*
No. (%) Normal renal tubular cells RCC
Total <0.001
Sex
Male 46 (73) 199.1 ± 13.1 106.7 ± 7.8 <0.001
Female 17 (27) 214.1 ± 18.5 92.9 ± 11.3 <0.001
P value† 0.54 0.345
Grade
I 9 (14) 176.7 ± 28.7 112.2 ± 17.9 0.048
II 29 (46) 209 ± 14.8 97.9 ± 9.9 <0.001
III 9 (14) 242.2 ± 20.1 122.2 ± 17.1 <0.001
IV 14 (23) 177.9 ± 28.2 96.4 ± 11.3 0.011
ND 2 (3) 240 ± 60 95 ± 65
P value‡ 0.257 0.556
Stage
Organ-confined (T1-2N0M0) 41 (65) 190.5 ± 13.4 94.9 ± 7.4 <0.001
Locally advanced (T3-4N0M0) 15 (24) 242 ± 18.5 120.7 ± 15.5 <0.001
Metastatic (N1-2 or M1) 7 (11) 194.3 ± 36.7 112.9 ± 18.1 0.099
P value‡ 0.129 0.215
Histological type
Conventional 54 (86) 209.3 ± 10.8 102.8 ± 7 <0.001
Non-conventional 9 (14) 166.7 ± 38.2 104.4 ± 16.9 0.15
P value† 0.167 0.929
NOTE: Expression of cytoplasmic EGFR protein was examined by immunohistochemistry on a scale from 0 to 300 (percent positive cells × staining 
intensity). Non-conventional type included papillary, chromophobe, sarcomatoid and collecting duct. Abbreviations: RCC, renal cell carcinoma; SE, 
standard error; TNM, tumor-node-metastasis; ND, not determined. *: paired sample t test, †: Independent-sample t test for two groups, ‡: One-
way ANOVA for three or more groupsJournal of Biomedical Science 2009, 16:82 http://www.jbiomedsci.com/content/16/1/82
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Immunohistochemical staining of cytoplastic EGFR in normal parenchymal and RCC tissues Figure 3
Immunohistochemical staining of cytoplastic EGFR in normal parenchymal and RCC tissues. Tissue sections of 
normal parenchymal tissues (A, C) or RCC (B, D) were from the same patient. The polyclonal anti-EGFR antibody was used to 
stain paraffin sections (A, B). Negative control was the omission of the primary antibody (C, D). The breast cancer used as a 
positive control for EGFR expression (E). Original magnification, × 200.
A B
C D
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Kaplan-Meier survival analysis of RCC patients Figure 4
Kaplan-Meier survival analysis of RCC patients. (A) Correlation of membranous EGFR expression (negative, 0; positive, 
+1 to +3) with survival (years after surgery) in RCC patients. (B) Correlation of cytoplasmic EGFR expression (total score: 
0~100, 101~200 and 201~300) with survival (years after surgery) in RCC patients. The log-rank test was performed to exam-
ine the association of EGFR with overall survival.
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sus cytoplasmic) might help select patients for different
approaches of EGFR targeted treatment.
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